Halozyme Therapeutics (HALO) announced the company entered into a global collaboration and exclusive license agreement with Takeda (TAK) in December 2025. The agreement provides Takeda with access to Halozyme’s Enhanze drug delivery technology, the leading proprietary recombinant human hyaluronidase PH20 enzyme, for use with vedolizumab. Vedolizumab is marketed globally as Entyvio. Under the terms of the agreement, Takeda will make an upfront payment to Halozyme, and potential future development and commercial milestone payments. Halozyme will also be entitled to up to low-mid single digit royalties on sales of products containing vedolizumab in combination with Enhanze.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme price target lowered to $75 from $79 at Morgan Stanley
- CoreWeave initiated, Shopify downgraded: Wall Street’s top analyst calls
- Skye Bioscience, Halozyme enter collaboration, license agreement
- Halozyme, Skye Bioscience announce global collaboration, license agreement
- Rybrevant FASPRO Approval and ENHANZE Royalties Reset Halozyme’s Long-Term Growth Outlook, Supporting a Buy Rating and $90 Target